Surgeon Simulator: Experience Reality
Bossa Studios · 2016 · $19.99 · Action · deal grade B
Measured on 2026-10-02 18:58 UTC, 3 days ago. The whole catalog is re-measured daily; a game that just launched can move fast between passes.
- Estimated net residual revenue: $646 to $969 per month
- Opportunity: $1.3k per month at x1.60 dormancy
- Estimated lifetime owners: 62.1k
- 58% positive across 1270 reviews · 7.5 reviews/month
Why it's flagged
- Developer silent for 4.7 years
- Studio active elsewhere (6 titles tracked), so this one may welcome a partner
- Last discounted 0 months ago, 9 sales in the last 12 months
- Proven demand elasticity: x1.4 review velocity during past deep sales
Analyst notes (AI-assisted)
Note written 2026-08-25; the live figures above take precedence over any numbers in it.
A VR-native surgical comedy game from 2016 that trades slapstick physics for anatomical absurdism across several brief, skill-based levels.
Surgeon Simulator: Experience Reality inhabits an odd niche: a licensed VR title with modest but stable monthly residuals and a narrow, satisfied core audience. The 57% positive score masks a real technical fragility (crash reports in recent reviews) that suggests the codebase needs stabilization work. For a publisher or platform holder, this is primarily a revitalization play, not an acquisition; for a VR specialist, the brand and IP may justify a modest engineering investment to unlock dormant players and prevent further decay. Most realistic play: revival.
- Risk: Recent crash logs in player reviews indicate runtime instability; VR middleware or engine dependencies may have drifted out of sync with current SDKs.
- Risk: Median session is under 3 hours; the title functions more as a novelty experience than a retention driver, limiting upside even with fixes.
- Risk: No developer updates in 54 months and zero community posts in the last year suggest institutional knowledge may be sparse; post-launch support was minimal.
This case as Markdown · Estimates carry ±30-50% error per title.